Karuna Therapeutics Inc
Change company Symbol lookup
Select an option...
KRTX Karuna Therapeutics Inc
CGNX Cognex Corp
SNTG Sentage Holdings Inc
XNXNX Nuveen New York Select Tax Free Income Portfolio
ITRI Itron Inc
NMZ Nuveen Municipal High Income Opportunity Fund
WTER Alkaline Water Company Inc
CASA Casa Systems Inc
PVBC Provident Bancorp Inc (Maryland)
AFRM Affirm Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Karuna Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on creating and delivering transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate, KarXT, is an oral modulator of muscarinic receptors that are located both in the central nervous system (CNS) and various peripheral tissues. It is initially developing KarXT, for the treatment of acute psychosis in patients with schizophrenia. The Company is for the treatment of psychosis in Alzheimer's disease (AD), which is the prevalent subtype of dementia-related psychosis (DRP). KarXT is a combination of xanomeline and trospium. It is advancing a pipeline of therapeutic programs to address the positive, negative and cognitive symptoms associated with schizophrenia and dementia-related psychosis (DRP). Its muscarinic receptors serve a number of physiological roles, including in cognitive, behavioral, sensory, motor and autonomic processes.

Closing Price
$277.42
Day's Change
16.11 (6.17%)
Bid
--
Ask
--
B/A Size
--
Day's High
278.25
Day's Low
256.64
Volume
(Average)
Volume:
1,303,903

10-day average volume:
1,249,254
1,303,903

Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease

6:30 am ET May 18, 2022 (BusinessWire) Print

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a virtual event on Wednesday, May 25, 2022, at 8:00 a.m. ET. The one-hour webcast event will highlight progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT for the treatment of psychosis in Alzheimer's disease.

The event will feature presentations from members of Karuna's leadership team. To register for the event, please click here.

The webcast of the event will be available on the Investor Relations page of Karuna's website at investors.karunatx.com.

About Karuna Therapeutics

Karuna Therapeutics is a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and neurological conditions. At Karuna, we understand there is a need for differentiated and more effective treatments that can help patients navigate the challenges presented by these severe and disabling disorders. Utilizing our extensive knowledge of neuroscience, we are harnessing the untapped potential of the brain in pursuit of novel pathways to develop medicines that make meaningful differences in peoples' lives. For more information, please visit www.karunatx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220518005282/en/

SOURCE: Karuna Therapeutics, Inc.

Investor Contact: 
Alexis Smith
518-338-8990
asmith@karunatx.com

Media Contact: 
Lauren Sneider
917-886-0247
lsneider@karunatx.com
comtex tracking

COMTEX_407381989/1006/2022-05-18T06:30:00

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.